ICH Announces Training Program

August 14, 2017

A pilot program will offer instruction on scientific and regulatory guidelines including training on GMPs and quality.

On August 14, 2017, the International Council for Harmonization (ICH) announced a training pilot program that will partner its Training Subcommittee with a group of trainers to provide instruction on ICH scientific and regulatory principles. ICH will evaluate the pilot program at the end of 2017 to determine a longer-term training strategy

The committee performed a needs assessment survey to determine which guidelines needed training. The following training will be provided:

Intermediate Course for DMF, ASMF, Module 3 Submissions in eCTD Format, Frankfurt, Germany, Nov. 6–7, 2017. ICH will provide more information in the future.

Intermediate Course for Regulatory Submissions in eCTD Format, San Diego, CA, USA, Oct. 17–18, 2017. ICH will provide more information in the future.

ICH GCP Training, Cambridge, MA, USA, Oct. 17–19, 2017. The workshop, which will be taught by members of FDA, the European Medicines Agency, and Health Canada, will advance understanding of ICH E6 and the revised E6(R2) guidelines. Information about the program can be found on the ICH website.

ICH Q1 Stability Training, Burlington, MA, USA, Oct. 11Â–13, 2017. The training will help participants understand expectations regarding stability testing. Information about the program can be found on the ICH website.

GMP for APIs (ICH Q7) Training, Tokyo, Japan - October 10-11, 2017. This course, run by Japan’s Pharmaceuticals and Medical Devices Agency and the Parenteral Drug Association, will offer insights from GMP inspectors and the requirements of ICH Q7. Information about the program can be found on the ICH website.

ICH-endorsed programs will include the ICH logo.

Source: ICH

Related Content:

The FDA Vaccines and Related Biologics Products Advisory Committee (VBPAC) unanimously voted on Oct. 15, 2021, to recommend an Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson (J&J) COVID-19 vaccine for adults aged 18 or older at least two months following initial vaccination. This decision comes just one day after a similar recommendation for the Moderna COVID-19 vaccine. The vote followed findings from two J&J clinical trials. One was the Phase III ENSEMBLE 2 study which evaluated booster doses of the company’s COVID-19 vaccine administered two months after the single-shot. According to a company press release, these findings suggested increased protection (94%) against moderate-to-severe COVID-19 in the United States. J&J’s other clinical trial was a Phase I/IIa study evaluating a booster dose given six months after the first shot. According to the press release, this demonstrated a nine-fold increase in antibody levels one week after the booster and a 12-fold increase four weeks after the booster. In addition to the clinical trials, data from a real-world study that was conducted from March to the end of July, and then extended to the end of August 2021, was also supplied to the council. This study showed stable vaccine effectiveness of 76% for COVID-19 related infections and 81% for COVID-19-related hospitalizations. There was no evidence of reduced effectiveness over the study duration of six months, which included the time period in which the Delta variant became dominant in the US. However, sequencing data was not available for analysis. “Today’s recommendation is based on the totality of evidence, with clinical and real-world data showing that while a single shot offers strong and long-lasting protection against COVID-19, a booster given after the single-dose primary vaccination increases protection, in particular against symptomatic COVID-19,” said Paul Stoffels, vice-chairman of the Executive Committee and chief scientific officer, Johnson & Johnson, in the press release. Source: Johnson & Johnson